Clinical trial

Metabolically Healthy Obesity Increases the Risks of MASLD and Hyperuricemia

Invitation only · Not applicable · 1 countries · Registry ID NCT07001865

Invitation onlyNot applicableObservational

What this study is about

Although metabolically healthy obesity (MHO) is often considered a relatively benign obesity, its association with the risk of metabolic dysfunction-associated steatotic liver disease (MASLD) and hyperuricemia remains unclear. This study examined the associations between MHO and other metabolic-obesity phenotypes with MASLD and hyperuricemia, and explored the mediating roles of metabolic indicators.This study included 11,712 and 13,846 participants from a health examination cohort at the First Affiliated Hospital of Ningbo University for MASLD and hyperuricemia analyses, respectively. Participants were classified into four metabolic-obesity phenotypes, with MHO defined as obesity without metabolic syndrome components. The outcomes were MASLD and hyperuricemia. Cox regression and mediation analyses were conducted to assess associations and mediating effects.

A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.

Basic eligibility

Age18 Years to 100 Years

SexAll

Healthy volunteersAccepted

ConditionMetabolic Dysfunction-Associated Steatotic Liver Disease, Metabolically Healthy Obesity, Hyperuricemia

Full registry criteria

Inclusion Criteria: 1. Underwent comprehensive health examinations at the Physical Examination Center of the First Affiliated Hospital of Ningbo University between 2017 and 2024; 2. Aged 18 years or older at baseline; 3. Completed an abdominal ultrasound examination during the health check-up. Exclusion Criteria: 1. Underweight status at baseline, defined as BMI \< 18.5 kg/m² ； 2. Missing data on height, weight, or components of the metabolic syndrome ; 3. Baseline diagnosis of MASLD or any other liver diseases 4. Baseline diagnosis of hyperuricemia

Treatments and study arms

The registry does not list a named intervention.

Primary outcomes

Incidence of MASLD and Hyperuricemia7 years

through study completion

Study locations

1 locations were listed when this page was built. The first 40 are shown.

the First Affiliated Hospital of Ningbo University Ningbo, Zhejiang, China, 315000, Ningbo, Zhejiang Province 315000 Recruiting🇨🇳 Ningbo, China

Open map